Cantor Fitzgerald Raises Earnings Estimates for ALX Oncology

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Equities research analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for shares of ALX Oncology in a research note issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now expects that the company will earn ($1.97) per share for the year, up from their previous estimate of ($2.21). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share.

Several other equities research analysts have also weighed in on the stock. Jefferies Financial Group raised shares of ALX Oncology from a “hold” rating to a “buy” rating and upped their target price for the stock from $2.00 to $3.00 in a report on Thursday, March 6th. Stifel Nicolaus reduced their price target on shares of ALX Oncology from $3.00 to $1.50 and set a “hold” rating on the stock in a research report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of ALX Oncology in a research report on Friday, March 7th. UBS Group reduced their price target on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating on the stock in a research report on Monday, January 27th. Finally, Piper Sandler upped their price target on shares of ALX Oncology from $8.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, March 6th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $4.14.

ALX Oncology Stock Down 3.0 %

ALXO opened at $0.75 on Thursday. The firm’s 50-day simple moving average is $1.22 and its 200-day simple moving average is $1.52. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. ALX Oncology has a twelve month low of $0.73 and a twelve month high of $17.83. The firm has a market cap of $39.96 million, a price-to-earnings ratio of -0.25 and a beta of 1.01.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Almitas Capital LLC acquired a new position in ALX Oncology during the 4th quarter valued at about $2,042,000. Bank of America Corp DE lifted its position in ALX Oncology by 492.9% during the 4th quarter. Bank of America Corp DE now owns 1,035,326 shares of the company’s stock valued at $1,729,000 after purchasing an additional 860,703 shares during the period. Bank of Montreal Can acquired a new position in ALX Oncology during the 4th quarter valued at about $1,380,000. Two Sigma Advisers LP lifted its position in ALX Oncology by 64.6% during the 4th quarter. Two Sigma Advisers LP now owns 823,900 shares of the company’s stock valued at $1,376,000 after purchasing an additional 323,400 shares during the period. Finally, Geode Capital Management LLC lifted its position in ALX Oncology by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 740,106 shares of the company’s stock valued at $1,236,000 after purchasing an additional 39,259 shares during the period. 97.97% of the stock is currently owned by institutional investors and hedge funds.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.